Skip to content
OpenHORIZON-HLTH-2027-01-IND-01HaDEAOne-off

Development of cell-free protein synthesis platforms for discovery and/or production of biologicals

Cell-free protein synthesis for the discovery and production of biological medicines.

Horizon Europe Research and Innovation Action (RIA) for the development of cell-free protein synthesis platforms that enable biological medicines to be discovered and produced faster and more efficiently.

Next deadline
91
days
17 February 2027
HORIZON-HLTH-2027-01-IND-01
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Development of cell-free protein synthesis platforms for discovery and/or production of biologicals?

Who
A consortium of at least three independent organisations from three different countries, of which at least one is from an EU Member State and the others from Member States or Associated Countries; research organisations, companies of any size, public authorities, foundations and associations can participate. Organisations from the United States can also receive EU funding.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition); Specific conditions, Eligibility conditions
What for
A Research and Innovation Action to develop cell-free protein synthesis platforms for the discovery and/or production of biological products, to strengthen an innovative and competitive European health industry.
Expected Outcome; Scope
What you get
A grant covering 100% of eligible costs; the Commission considers an EU contribution of €6 to 8 million per project appropriate. The indicative budget for the topic is €24.5 million, expected to fund 4 projects.
Specific conditions (Expected EU contribution per project, Indicative budget); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal from 29 October 2026 until 17 February 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B and, if the proposal includes clinical studies, the annex on clinical studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.
Planned opening; Deadline(s); Application and evaluation forms; General Annex F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

Strengthening an innovative and competitive European health industry.

01
Streamlined development and production
The biopharmaceutical industry gains access to streamlined development and production processes for peptide- or protein-based biological medicines.
02
Improved and decentralised production
Health systems benefit from improved or decentralised production systems for innovative peptide- or protein-based health technologies that improve health and care.
03
Better access to medicines
Citizens and patients gain better access to available and affordable medicines based on biological substances.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals. - Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care. - Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries:
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
04
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
05
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
06
Subject to restrictions for the protection of European communication networks.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €6 million to €8 million per project appropriate.
€24.5m · Indicative topic budget, expected to fund 4 projects.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants), and the same costs may never be declared under two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

17
FEB
HORIZON-HLTH-2027-01-IND-01 closes 17 February 2027
Open since 29 October 2026
Planned opening; Deadline(s)Active
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative data of the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 40 pages)
  • Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Applications via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Actual costs in accordance with General Annex G and the Horizon Europe Model Grant Agreement; indirect costs at a flat rate of 25%. Funding rate 100%.
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 6

Subtitle
Subtitle: ChangedShow
Before

Celvrije eiwitsynthese voor ontdekking en productie van biologische geneesmiddelen.

Now

Cell-free protein synthesis for the discovery and production of biological medicines.

Description
Description: ChangedShow
Before

Projecten ontwikkelen platforms voor celvrije eiwitsynthese die de ontdekking en/of productie van biologische geneesmiddelen stroomlijnen. De biofarmaceutische industrie krijgt daarmee toegang tot snellere, flexibelere en duurzamere ontwikkel- en productieprocessen.

Now

Projects develop cell-free protein synthesis platforms that streamline the discovery and/or production of biological medicines. This gives the biopharmaceutical industry access to faster, more flexible and more sustainable development and production processes.

Short description
Short description: ChangedShow
Before

Horizon Europe-onderzoeksactie (RIA) voor de ontwikkeling van platforms voor celvrije eiwitsynthese, waarmee biologische geneesmiddelen sneller en efficiënter ontdekt en geproduceerd kunnen worden.

Now

Horizon Europe Research and Innovation Action (RIA) for the development of cell-free protein synthesis platforms that enable biological medicines to be discovered and produced faster and more efficiently.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 4 projecten.

Now

Indicative topic budget, expected to fund 4 projects.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 6 mln tot € 8 mln EU-bijdrage per project passend.

Now

No binding maximum; the Commission considers an EU contribution of €6 million to €8 million per project appropriate.

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants), and the same costs may never be declared under two different EU actions (General Annex G).

Search engine title
Celvrije eiwitsynthese voor biologicals (Horizon HLTH) becomes Cell-free protein synthesis for biologicals (Horizon HLTH)
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe-onderzoeksactie (circa € 6-8 mln per project) voor platforms voor celvrije eiwitsynthese van biologische geneesmiddelen.

Now

Horizon Europe research action (approx. €6-8 million per project) for cell-free protein synthesis platforms for biological medicines.

Keywords
biologische geneesmiddelen, celvrije eiwitsynthese, Cluster 1 Health, farmaceutische productie, Horizon Europe, HORIZON-HLTH-2027-01-IND-01 becomes biological medicines, cell-free protein synthesis, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-01-IND-01, pharmaceutical production
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat becomes Application form Part A: administrative data of the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 40 pages); Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Applications via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Werkelijke kosten volgens General Annex G en de Horizon Europe-modelovereenkomst; indirecte kosten forfaitair 25%. Financieringspercentage 100%.

Now

Other costs: Actual costs in accordance with General Annex G and the Horizon Europe Model Grant Agreement; indirect costs at a flat rate of 25%. Funding rate 100%.

Why this scheme
Why this scheme: ChangedShow
Before

Een innovatieve en concurrerende Europese gezondheidsindustrie versterken.

Now

Strengthening an innovative and competitive European health industry.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; onderzoeksinstellingen, bedrijven van elke omvang, overheden, stichtingen en verenigingen kunnen deelnemen. Ook organisaties uit de Verenigde Staten kunnen EU-financiering krijgen.

What for: Een onderzoeks- en innovatieactie om celvrije eiwitsyntheseplatforms te ontwikkelen voor het ontdekken en/of produceren van biologische producten, ter versterking van een innovatieve en concurrerende Europese gezondheidsindustrie.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 6 tot 8 miljoen per project passend. Het indicatieve budget voor het topic is € 24,5 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 29 oktober 2026 tot uiterlijk 17 februari 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en deel B en, als het voorstel klinische studies omvat, de bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different countries, of which at least one is from an EU Member State and the others from Member States or Associated Countries; research organisations, companies of any size, public authorities, foundations and associations can participate. Organisations from the United States can also receive EU funding.

What for: A Research and Innovation Action to develop cell-free protein synthesis platforms for the discovery and/or production of biological products, to strengthen an innovative and competitive European health industry.

What you get: A grant covering 100% of eligible costs; the Commission considers an EU contribution of €6 to 8 million per project appropriate. The indicative budget for the topic is €24.5 million, expected to fund 4 projects.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal from 29 October 2026 until 17 February 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B and, if the proposal includes clinical studies, the annex on clinical studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.

Goals
Goals: 3 removed, 3 newShow
Removed

Gestroomlijnde ontwikkeling en productie De biofarmaceutische industrie krijgt toegang tot gestroomlijnde ontwikkel- en productieprocessen voor biologische geneesmiddelen op basis van peptiden of eiwitten.

Betere en decentrale productie Zorgstelsels profiteren van verbeterde of decentrale productiesystemen voor innovatieve gezondheidstechnologie met peptiden of eiwitten, die gezondheid en zorg verbeteren.

Betere toegang tot geneesmiddelen Burgers en patiënten krijgen betere toegang tot beschikbare en betaalbare geneesmiddelen op basis van biologische stoffen.

New

Streamlined development and production The biopharmaceutical industry gains access to streamlined development and production processes for peptide- or protein-based biological medicines.

Improved and decentralised production Health systems benefit from improved or decentralised production systems for innovative peptide- or protein-based health technologies that improve health and care.

Better access to medicines Citizens and patients gain better access to available and affordable medicines based on biological substances.

Show 5 earlier versions

29 October 2026scheme · version 5

De call is op 29 oktober 2026 geopend. Voorstellen kunnen tot en met 17 februari 2027 worden ingediend.

Status
Opening soon becomes Open

19 October 2026scheme · version 4

Conditions
Conditions: 2 removed, 6 newShow
Removed

Consortium van minimaal 3 partijen Drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minimaal één uit een lidstaat (General Annex B).

Entiteiten uit de Verenigde Staten subsidiabel Juridische entiteiten gevestigd in de Verenigde Staten kunnen EU-financiering ontvangen, vanwege de openstelling van NIH-programma's voor Europese onderzoekers.

New

To be eligible for funding, applicants must be established in one of the following countries:

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

Subject to restrictions for the protection of European communication networks.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; onderzoeksinstellingen, bedrijven van elke omvang, overheden, stichtingen en verenigingen kunnen deelnemen. Ook organisaties uit de Verenigde Staten kunnen EU-financiering krijgen.

What for: Een onderzoeks- en innovatieactie om celvrije eiwitsyntheseplatforms te ontwikkelen voor het ontdekken en/of produceren van biologische producten, ter versterking van een innovatieve en concurrerende Europese gezondheidsindustrie.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 6 tot 8 miljoen per project passend. Het indicatieve budget voor het topic is € 24,5 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 29 oktober 2026 tot uiterlijk 17 februari 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en deel B en, als het voorstel klinische studies omvat, de bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals. - Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care. - Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: biologische geneesmiddelen, celvrije eiwitsynthese, Cluster 1 Health, farmaceutische productie, Horizon Europe, HORIZON-HLTH-2027-01-IND-01
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat
Goals
Goals: 3 newShow
New

Gestroomlijnde ontwikkeling en productie De biofarmaceutische industrie krijgt toegang tot gestroomlijnde ontwikkel- en productieprocessen voor biologische geneesmiddelen op basis van peptiden of eiwitten.

Betere en decentrale productie Zorgstelsels profiteren van verbeterde of decentrale productiesystemen voor innovatieve gezondheidstechnologie met peptiden of eiwitten, die gezondheid en zorg verbeteren.

Betere toegang tot geneesmiddelen Burgers en patiënten krijgen betere toegang tot beschikbare en betaalbare geneesmiddelen op basis van biologische stoffen.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
17 November 2026 by the Twin editors
Start your application

Start your HORIZON-HLTH-2027-01-IND-01 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.